Augtyro Dosage
Generic name: REPOTRECTINIB 40mg
Dosage form: capsule
Drug class: Multikinase inhibitors
Medically reviewed by Drugs.com. Last updated on Jun 13, 2024.
Patient Selection
NSCLC
Select patients for the treatment of locally advanced or metastatic NSCLC with AUGTYRO based on the presence of ROS1 rearrangement(s) in tumor specimens. An FDA-approved test to detect ROS1 rearrangements for selecting patients for treatment with AUGTYRO is not currently available.
Solid Tumors
Select patients for the treatment of solid tumors with AUGTYRO based on the presence of NTRK1/2/3 rearrangements in tumor specimens. An FDA-approved test to detect NTRK1/2/3 rearrangements for selecting patients for treatment with AUGTYRO is not currently available.
- •
- In patients with secretory breast cancer or mammary analogue secretory cancer, consider treatment without confirmation of NTRK rearrangements in tumor specimens.
Important Information Prior to Initiating AUGTYRO
Prior to initiating AUGTYRO, discontinue strong and moderate CYP3A inhibitors for 3 to 5 elimination half-lives of the CYP3A inhibitor.
Recommended Evaluation and Testing Before Initiating AUGTYRO
Prior to initiation of AUGTYRO, evaluate:
- •
- liver function tests including bilirubin
- •
- uric acid level
Recommended Dosage
The recommended dosage of AUGTYRO for adult and pediatric patients 12 years of age and older is 160 mg taken orally once daily with or without food for 14 days, then increase to 160 mg twice daily and continue until disease progression or unacceptable toxicity.
Dosage Modifications for Adverse Reactions
The recommended dosage reductions of AUGTYRO for the management of adverse reactions are provided in Table 1.
Dose |
Dose Reduction |
|
First |
Second |
|
160 mg Once Daily |
120 mg Once Daily |
80 mg Once Daily |
160 mg Twice Daily |
120 mg Twice Daily |
80 mg Twice Daily |
Recommended dosage modifications of AUGTYRO for the management of adverse reactions are provided in Table 2.
*Graded per Common Terminology Criteria for Adverse Events v4.03 | ||
Adverse Reaction |
Severity* |
Dosage Modification |
Central Nervous System Effects |
Intolerable Grade 2 |
|
Grade 3 |
|
|
Grade 4 |
|
|
Interstitial Lung Disease (ILD)/Pneumonitis |
Any Grade |
|
Hepatotoxicity |
Grade 3 |
|
Grade 4 |
|
|
ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 1.5 times ULN (in the absence of cholestasis or hemolysis) |
|
|
Creatine Phosphokinase (CPK) Elevation |
CPK elevation greater than 5 times ULN |
|
CPK elevation greater than 10 times ULN or second occurrence of CPK elevation of greater than 5 times ULN |
|
|
Hyperuricemia |
Grade 3 or Grade 4 |
|
Other Clinically Relevant Adverse Reactions |
Intolerable Grade 2 or Grade 3 or Grade 4 |
|
Administration
Take AUGTYRO at approximately the same time each day with or without food.
Swallow AUGTYRO capsules whole. Do not open, chew, crush, or dissolve the capsule prior to swallowing. Do not take any AUGTYRO capsules that are broken, cracked, or damaged.
If a dose of AUGTYRO is missed or if vomiting occurs at any time after taking a dose, skip the dose and resume AUGTYRO at its regularly scheduled time.
More about Augtyro (repotrectinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.